WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Review on: Dostarlimab and Role on Rectal Cancer

Akshay R Pawar[1]; Rekha Goukonde [2]; Ravindra G. Rathod [3]; Dr. Gajanan Sanap [4]

[1,2,3,4]LBYP College of Pharmacy, Chh. Sambhajinagar- 431111, Maharashtra, India

A B S T R A C T

This article summarizes the milestones in the development of dostarlimab leading To approval. Dostarlimab is a humanized monoclonal antibody programmed death-1 (PD-1) receptor Antagonist being developed for the treatment of various cancers. Based on preliminary results from the GARNET trial Dostarlimab has recently been approved in the EU and USA for the treatment of adult patients with mismatch repair defcient Recurrent or advanced endometrial cancer. Dostarlimab associated with Clinically meaningful and durable antitumor activity with an

acceptable safety profile for Patients with deficient mismatch mutation repair endometrial cancers after prior Platinum-based chemotherapy. Immune checkpoint inhibitors have demonstrated significant clinical activity across various tumor subtypes; however, their utility in gynecologic malignancies has thus far proven modest. Dostarlimab, a PD-1 inhibitor, has demonstrated preliminary evidence of clinical activity and acceptable safety profile in patients with across recurrent EC, particularly microsatellite instability-hypermutated/DNA mismatch repair-deficient EC. This review outlines existing data for the efficacy and safety of dostarlimab in recurrent or advanced-stage EC

Keywords: Dostarlimabendometrial, Carcinomagynecologic, Endometrial immunocheckpoint, Inhibitorimmunotherapy, PD-1 inhibitor TSR-042

Introduction

Dostarlimab (TSR-042, JEMPERLI) is a humanised monoclonal antibody (mAb) of the immunoglobulin G (IgG) 4 isotype that has been approved for use. Its goal is to bind to PD-1 and prevent interaction with its ligands, PD-L1 and PD-L2, by blocking inter-action. Dostarlimab was made from a mouse monoclonal antibody that had its heavy- and light-chain complementarity- determining regions grafted onto human cells Following affinity maturation by mammalian cell display and somatic hypermutation, employing the AnaptysBio SHM-XEL system, onto the germline variable region frameworks of their closest human species orthologs. Dostarlimab singleagent anticancer activity was examined using humanised mice models due to the drug's absence of cross-reactivity to mouse PD-1. Dostarlimab showed anticancer effect in this model system, which was determined by tumour growth inhibition and was linked to a rise in immune cell infiltration. These results show dostarlimab to be a strong anti-PD-1 receptor antagonist with characteristics that warrant further clinical testing in cancer patients. Following affinity maturation by mammalian cell display and somatic hypermutation, employing the AnaptysBio SHM-XEL system, onto the germline variable region frameworks of their closest human species orthologs. as a result of. **(1)**

Dostarlimab(Jemperli) is ananti-PD-1 monoclonal antibody. The ongoing GARNET trial(NCT02715284) is a phase I,multi-center, open- marker, single-arm study designed to assess the safety andanti-tumor exertion of dostarlimab monotherapy in cases with advanced solid excrescences.19 Dostarlimab has demonstrated clinical exertion in colorful excrescence types, including mismatch form-deficient/ microsatellite insecurity-high endometrial cancer, colorectal cancer, andnon-small cell lung cancer(2) Dostarlimab single- agent anticancer efficacity was assessed using humanized Mice models because of the dearth ofcross- PD- 1. In this model System, the anticancer exertion of dostarlimab was demonstrated by the reduction of excrescence Development, which was reactivity with mouse

associated with stoked seditious cell infiltration. These Results demonstrate the energy of dostarlimab as ananti-PD-1 receptor opponent with parcels that call for fresh clinical trials in cancer cases. Dostarlimab, request mice models because of the dearth of cross reactivity with mouse PD- 1. In this model system, the anticancer exertion of dostarlimab was demonstrated by the reduction of excrescence development, which was associated with stoked seditious cell infiltration. These results demonstrate the energy of dostarlimab as ananti-PD-1 receptor opponent with parcels that call for fresh clinical trials in cancer cases. Dostarlimab, retailed under the trade name Jemperli, is presently being delved in several different solidtumor types as part of the phase I GARNET trial(NCT02715284), which is both a lozenge acceleration and a safety/ acceptability cohort expansion(3) Dostarlimab is a humanized IgG4κ antibody that binds PD- 1 on T cells and blocks relations with its ligands PD- L1 and PD- L2, thereby cranking vulnerable responses. To help for- mation of half- antibodies, each heavy chain of the antibody contains a mutation(S228P) to promote stabilization of disulfide bonds between the two heavy chains.(4) Data from the GARNET trial demonstrate durable antitumor responses with dostarlimab monotherapy in cases with dMMR and MMRp endometrial cancers and non – EC dMMR solid excrescences.(5) Dostarlimab is a programmed death 1(PD- 1) asset approved in the US as monotherapy in cases with mismatch form deficient(dMMR) advanced/ intermittent endometrial cancer(EC) that has progressed on or after platinum- grounded chemotherapy or dMMR solid tumoursthat have progressed on or after previous treatment, with no satisfactory indispensable treatment options; and in the EU as monotherapy in cases with dMMR/ microsatellite insecurity-- high(MSI- H) advanced/ intermittent EC that has progressed on or after platinum-

grounded chemotherapy.(6) Dostarlimab is certified as monotherapy for diagnosing adult cases with reenacting or advanced mismatch form insufficiency/ microsatellite insecurity – high endometrial cancer that has advanced while entering a platinum- containing authority or following treatment that comported of platinum in the history. Dostarlimab has been showing antitumor exertion that's clinically applicable, with complaint- control rates of57.7, objective response rates of42.3, and safety biographies that are commensurable with those of certifiedanti-PD-1 drugs

Pharmacokinetics :

The Supplementary styles go into great detail about the blood slice routine. Enzyme- linked immunosorbent assays were used to measure the amounts of dostarlimab in the blood(Supplementary styles). WinNonlin Version8.0, Pharsight, Mountain View, California, and two- compartmental logical ways were used for the PK analysis(NONMEM, ICON Development results, Ellicott City, MD). Time to Cmax(Tmax), outside(Cmax), and minimum(Ctrough) serum dostarlimab attention were the measured values. The area under the serum dostarlimab attention- time wind(AUC) was calculated using the direct trapezoidal system to determine the total systemic exposure to dostarlimab(direct up, log down). The longevity of terminal elimination was reckoned as ln(2)/ k. Before studying the fixed- cure fashion in part 2A and farther analysing combined data from both corridor 1 and 2A, body weight was analysed as a covariate for dostarlimab concurrence.(7) in the pharmacokinetics characteristics of dostarlimab grounded on gender, age, race, excrescence type, or renal or hepatic impairment. Although, there are no studies conducted to determine whether dostarlimab- gxly is carcinogenic or genotoxic. Fertility studies have been performed for this medicine on monkeys which, after repeating boluses for one and three months, set up no significant goods on manly or womanish reproductive organs, although utmost creatures in these studies weren't sexually mature by the time of study(8) The mean terminal elimination half- life of Dostarlimab is25.4 days, and the mean concurrence of Dostarlimab is0.007 L/ h. There are no data regarding overdose with Dostarlimab. Symptoms of overdosage are likely to be harmonious with the adverse effect profile of Dostarlimab and may thus involve significant vulnerable- mediated responses(9) Dostarlimab pharmacokinetics was direct and doseproportional. Minimal RO was observed at the RP2D,. harmonious with former results, and was maintained throughout treatment(10) Dostarlimab attention of 222, 229, 232, and 287 g/ mL were discovered in four of the 19 samples(at a perceptivity of 500 ng/ mL). Four of the nine people with dostarlimab attention lesser than or equal to 125 ng/ mL were verified to have ADAs, and onhad a medicine attention of 171 ng/ mL or advanced!(early1 day 5). fresh testing revealed that the titer determination and signal discovery capabilities of the ADA fashion were innocent by the medicine attention(11)

Pharmacodynamics

As dostarlimab doesn'tcross-react with mouse PD- 1, the capability of dostarlimab to parade antitumor exertion in vivo was assessed in humanized mouse models representative of mortal non – small cell lung cancer and bone(12) Dostarlimab is an immunotherapy that facilitates the body's endogenousanti- excrescence vulnerable response in the treatment cancer. It's administered over a span of 30 beats via intravenous infusion every three to six weeks depending on the cycle. Agents that intrude with the PD- 1/ PD- L1 pathway, including dostarlimab, remove an important vulnerable system inhibitory response and may therefore induce vulnerable- mediated adverse responses which can be severe or fatal. These responses can do in any organ system and can do at any time after starting remedy, and while they most constantly manifest during remedy they may also appear after discontinuing the causative agent. Cases entering remedy with dostarlimab should be covered nearly For validation of an underpinning vulnerable mediated response and estimated and treated incontinently if an vulnerable- mediated(13)

Mechanism of action:

Dostarlimab(Jemperli ™) or dostarlimab- gxly is a humanized mAB which acts as an antagonist for programmed death- 1(PD- 1) receptors. It's being developed by Glaxo Smith Kline (GSK) under a license from AnaptysBio Inc for the treatment of several forms of cancer including endometrial cancer, colorectal cancer, ovarian cancer, cancer of the head and neck, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), scaled cell cancer(SCC), fallopian tube cancer, pancreatic cancer, and numerous further. According to primary findings from the GARNET trial, dostarlimab has lately been approved (22 April 2021) for grown-ups with advanced or intermittent advanced mismatch form-deficient endometrial cancer (dMMR) in the EU and USA. The cure of dostarlimab that's generally recommended is 500 mg every 3 weeks(for the first four boluses), after the fourth cure, 1000 mg every 6 weeks is administered until complaint progression or any inferior toxin is(8) The first- in- mortal study,4010-01-001, else known as the GARNET trial(NCT02715284), estimated dostarlimab pharmacokinetics(PK), pharmacodynamics(PD), tolerability, clinical exertion and safety across multiple solid cancer types, which included endometrial, NSCL and cancer of the ovaries and fallopian tubes. A modified 3 3 design was used to estimate three weight-grounded boluses (1, 3 and 10 mg/ kg) administered every 2 weeks intravenously in Part 1. Part 2A used two fixed- cure rules, 500 mg every 3 weeks intravenously, and 1000 mg every 6 weeks intravenously administered in in 2B. Data from Part 1 demonstrated a maximum receptor residency at2.4 g/ mL dostarlimab serum attention. likewise, a PK model was constructed using the PK data from Part 1 to prognosticate dostarlimab attention that would exceed those leading to minimal receptor residency at fixed boluses.

Also, Part 2A demonstrated cure-commensurable PK and the median serum trough attention to be roughly 40 and 50 ng/ mL after a single cure of 500 mg and 1000 mg,

14) Herein we Insilco delved a new medium thorough which the great success of Dostarlimab may be achieved in the recent CRC clinical trial. Our paper showed that Dostarlimab could bind explosively and directly to IL- 6 with a list affinity which is similar to its bindingB7- 2 Receptors. According to our novel grounded on docking analysis targeting of IL- 6 may be the main cause for the success of this CRC clinical trial Moreno present in cancer cells. by

blocking the inhibitory effect of catla4 on the induction of T cells against excrescence cells. CTLA4 is a seeker gene which has been intertwined in the development of colorectal cancer (CRC).

CTLA- 4 is transiently expressed on some actuated T cells.(15) Upregulation of the PD- 1 ligands PD- L1 and PD- L2 occurs in some excrescences. List of the PD- 1 ligands to the PD- 1 receptor that's expressed on T- cells inhibits T- cell proliferation. also, the PD- 1 pathway signaling can reduce the capability of T- cells to descry and exclude cancer cells; blocking this pathway can thus inhibit this exertion. Dostarlimab is a humanized monoclonal antibody of the G4 isotype that binds to the PD- 1 receptor and blocks its commerce with PD- L1 and PD- L2, thereby enhancing the antitumor vulnerable response. In preclinical studies, inhibition of PD- 1 exertion redounded in dropped endometrial excrescence growth.(16) T cells are pivotal for cancer immunotherapy because they're crucial intercessors of antitumor action, feting and replying to tumour- expressing antigens. still, T cells aren't as effective against cancer as one might assume.(13) " This is incompletely due to T cells of an inhibitory characterized by the presence of an inhibitory Programmed Cell Death 1(PD- 1) receptor on the Programmed Cell Death 1(PD- 1) receptor on the T- cells and as well as B-cells.PD- 1 is an vulnerable system.(17) A pharmacokineticstudy for dostarlimab- gxly was performed on cases with solid excrescences which



1. Fig: illustration of the activity of dostarlimab against cancer cell the PD1 inhibitor (dostarlimab) inhibits the commerce of T- cellsover- expressing PD- 1 protein with the ligands(PD- L1) present in cancer cells.

Included 150 endometrial cancer cases. It was noted that there was a commensurate increase in mean Cmax, AUC0 − inf and AUC0 − τ over the cure range of1.0 – 10 mg/ kg. also, the mean cycles of Cmax and AUC0 − τ after the administration of 500 mg dostarlimab formerly every 3 weeks was reported to be in the range of 171 µg/ mL and,730 µg h/ mL, independently, and 309 µg/ mL and,820 µg • h/ mL, independently, at a cure of 1000 mg administered formerly every 6 weeks. also, the study also substantiated the mean steady- state volume of the distribution of dostarlimab to be around5.3 L, and the mean steady- state concurrence to be in the range of0.007 L/ h. There were no clinically significant differences observed in the pharmacokinetics characteristics of dostarlimab grounded on gender, age, race, excrescence type, or renal or hepatic impairment. Although, there are no studies conducted to determine whether dostarlimab- gxly is carcinogenic or genotoxic. Fertility studies have been performed for this medicine on monkeys which, after repeating boluses for one and three months, set up no significant goods on manly or womanish reproductive organs, although utmost creatures in these studies weren't sexually mature by the time of(18) Dostarlimab could achieve this advance is due to its capability to block PD- 1(B7- H1). Unexpectedly, we insilico, discovered that Dostarlimab displayed a high binding a nity(329 kcal/ spook) with good quality model(LGScore(4.540) to IL- 6R and this binding a nity is similar with its binding a innity to B7- 2 receptors(-332.35 kcal/ spook)(LGScore(2.540). also, we discovered that Dostarlimab could bind to CTLA- 4 with binding a nity(-305.91 kcal/ spook). As a result, this means that dostarlimab not only bind with high a nity to B7- 2 or BH- 3(PD- 1) but also to IL- 6R and CATLA4. According to our new results could experimentally inhibit IL- 6, CTLA- 4 and B7 receptors and this may explain the 100(15) Dostarlimab is an IgG4 humanized monoclonal antibody targeted against the mortal programmed death receptor- 1(PD- 1). 6 PD- 1 receptors are set up on T- cells and, when actuated, serve to inhibit vulnerable responses some cancers impact this system by over expressing PD- 1 ligands, thereby effectively inhibiting theanti- excrescence vulnerable response that would generally essay to destroy the cancerous cell(19

Recommended dosage and side effects of dostarlimab

Dostarlimab(Jemperli ™, dostarlimab- gxly) is ananti-PD-1, mono- Clonal IgG4 antibody that's produced from a mouse hybridoma that Blocks the antigen- receptor exertion of PD- L1 and PD- L2 hence normal- Izing the vulnerable response. Its medium of action is in agreement With other PD- 1/ PD- L1 impediments. It got approved on April 22, 2021 for The treatment of endometrial cancer(22) and came in the spotlight as a feasible treatment for CRC after this trial was conducted. farther operation of This medicine includes the treatment of multitudinous cancers including Pancreatic cancer, ovarian cancer, fallopian tube cancer,non-small cell Lung cancer(NSCLC), and small- cell lung(21) dry eye are common side goods of cases taking

ICIs.39, 40 For case, the FDA markers of both dostarlimab and cemiplimab(LIBTAYO, Regeneron Pharmaceuticals, Tarrytown, NY) list uveitis, iritis, other optical seditious venom as implicit side(22) Dostarlimab caused grade 3 or 4 treatment- related adverse events in 58 of cases. Immunotherapy-related adverse events were seen in 23 of cases, including grade 3 or 4 events in 8 of women. In all, 9 of cases discontinued treatment due to adverse events. No treatment- related mortality was seen. The main side goods were fatigue(18), diarrhea(15), nausea(14) and delicacy(12). Grade 3 or grade 4 adverse events were observed in3.2 of cases anemia, aspartate transaminase(AST) or aspartate aminotransferase(ALT) elevations, increase of amy-lase and lipase, diarrhea, fatigue, hyperglycemia(23)

Rectal cancer

Cases enrolled in this study were diagnosed with dMMR, stage II or III Rectal cancer. The detailed registration criteria included age lesser than 18 times, no signs of distant metastases, an Eastern Cooperative Oncology Group(ECOG) performance status score of 0or 1, and no former exposure to immunotherapy, chemotherapy, or radiation for the rectal excrescence. The primary endpoints reported then included the overall response to neoadjuvant dostarlimab remedy and 1 time sustained clinical complete response(cCR) after completion of dostarlimab remedy. Sixteen cases were signed and treated with dostarlimab. Twelve of these cases have entered the medicine for longer than 6 months and have completed the nine planned cycles of dostarlimab. The chance of the 12 successive cases achieving a cCR was 100(95 confidence interval(CI), 74 to 100), and excrescence eradication was observed using endoscopy, rectal glamorous resonance imaging, and 18F- fluorodeoxyglucose – positron- emigration tomography. During the median followup period of one time, no cases needed surgery, radiotherapy or chemotherapy. To date, 4 cases have achieved 12 months of sustained cCR after the completion of dostarlimab treatment alone. respectable toxin passed in 12 of the 16patients(75; 95 CI, 48 to 92) without any grade 3 or advanced adverse events. Reported treatment with single- agent dostarlimab(lasted for 6 months) with a 100 cCR in 12 cases with dMMR, LARC who Hadn't experienced radiation or surgery(24) In a recent clinical trial, NCT04165772, the following crucial eligibility criteria were discourage- minant of Dostarlimab success no substantiation of distant metastases, no former treatment with immunotherapy, chemotherapy or radiation for the rectal excrescence, and no active au-toimmune or contagious complaint or treatment with immunosuppressive remedy. Patientswith a clinical complete response passed no operative

follow- up. The lack of residual complaint on digital and endoscopic rectal examinations, as well as the absence of residual illness on rectal MRI, with no limited prolixity on T2- ladened imaging, was regarded as a clinical complete response. The overall response to neoadjuvant Dostarlimab ther- apy with or without chemoradiotherapy satisfied the criteria for the primary endpoint. In 12 successive cases who had completed 6 months of remedy, the chance of cases who had a clinical complete response was 100 During the 12- month standard Follow- up period, no cases entered chemoradiotherapy, and no cases passed sur- Gical resection. The pathophysiological full response wasn't assessed because none of the12 cases who completed 6 months of Dostarlimab medicatio In a recent clinical trial, NCT04165772, the following crucial eligibility criteria were discourage- minant of Dostarlimab success no substantiation of distant metastases, no former treatment with immunotherapy, chemotherapy or radiation for the rectal excrescence, and no active au-toimmune or contagious complaint or treatment with immunosuppressive remedy. Patientswith a clinical complete response passed no operative follow-up. The lack of residual complaint on digital and endoscopic rectal examinations, as well as the absence of residual illness on rectal MRI, with no limited prolixity on T2- ladened imaging, was regarded as a clinical complete response. The overall response to neoadjuvant Dostarlimab ther- apy with or without chemoradiotherapy satisfied the criteria for the primary endpoint. In 12 successive cases who had completed 6 months of remedy, the chance of cases who had a clinical complete response was 100 During the 12- month standard Follow- up period, no cases entered chemoradiotherapy, and no cases passed sur- Gical resection. The pathophysiological full response wasn't assessed because none of the12 cases who completed 6 months ofhad surgery.

Likewise had surgery. likewise, No illness progression or rush passed in any of the 16 cases that were enrolled, And they're all still alive. The major endpoint for response continuity(sustained clinical Complete response at 12 months) isn't included in the futurity of the study. The remedial Response was quick, with 81 of cases passing symptom relief within 9 weeks of Starting Dostarlimab.



Fig: The administration of anti-PD-1 antibody dostarlimab achieved clinical complete remission in the cases with dMMR, locally advanced rectal cancer. dMMR mismatch form- insufficiency, CRC colorectal cancer, pCR pathological complete response, cCR clinical complete response, PD- programmed death protein 1, PD- L1 programmed death ligand- 1

An endoscopic complete response at the 3- month Examination, but only two had a radiographic complete response. In 12 of the 16 cases,. There were adverse events of any inflexibility(75, CI, 48 – 92). There were no adversity Incidents of grade 3 or advanced reported. In one case, aberrant thyroid function was Discovered but that represented 6 of the adversities. Neoadjuvant immunotherapy has been studied in a variety of solid excrescences, including Those that are known to be sensitive to checkpoint leaguer in the environment of metastatic Illness, similar as NSCLC, urothelial melanoma, and carcinoma. The situations of exertion reported In those excrescence types were nowhere near as high as the situations seen in people with mismatch form-deficient rectal cancer. One possible contributing aspect is that we administers 6 months of immunotherapy, whereas the other exploration looked at shorter checkpoin leaguer exposures. In mismatch repairdeficient excrescences, immunotherapy responses have Been set up to evolve over months rather than weeks. Why these localized mismatch form-Deficient rectal excrescences respond so much better than metastatic colorectal malice is An intriguing content. Despite the presence of molecular features at birth that was like Those of the excrescences estimated in our study, the rate of imagingbased complete response of Mismatch form-deficient colorectal excrescences was11.1 in a study involving cases with Metastatic complaint who hadn't preliminarily entered any treatment. The implicit influence of the gut microbiome on cancers of the gastrointestinal system Was hypothecated. An adding body of substantiation supports the immunomodulatory part of specific bacterial species in enhancing theanti-tumor vulnerable response, which Is boosted by checkpoint leaguer. Although the results of our study are promising, Especially considering that 12 successive cases had a clinical full response, the major Study limitations are as follows the study is small and only represents the experience of One institution. These findings need to be replicated in a larger prospective cohort that Includes cases from a variety of ethnical and ethnical backgrounds and balances academic And community(25)

Conclusion

Dostarlimab and access to a medical platoon that will help cover cases like in the trial NCT04165772 and take action if the tumour returns should both be made intimately available. The strategy, in our opinion, will be the way to treat cancer in the future. Basedhe type and subtype of the cancer, and such a spectacular response as shown with Dostarlimab in cases with rectal cancer, it's encouraging to suppose that we're on the correct path to chancing a dramatic match for the other tumours.

References

1) Kumar, Sujatha, et al. “Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.” MAbs. Vol. 13. No. 1. Taylor & Francis, 2021.

2) Kristeleit, Rebecca, et al. “Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.” International Journal of Gynecologic Cancer 32.10 (2022).

3) Alkholifi, Faisal K., and Rana M. Alsaffar. “Dostarlimab an Inhibitor ofPD -1/PD-L1: A New Paradigm for the Treatment of Cancer.” Medicina58.11 (2022): 1572**.**

4) Kaplon, Hélène, et al. “Antibodies to watch in 2022.” MAbs. Vol. 14. No. 1. Taylor & Francis, 2022.

5) Moreno, Victor, et al. “Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.” Clinical Lung Cancer (2022).

6) Tinker, Anna V., et al. “2022-RA-1009-ESGO Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study.” (2022).

7) Patnaik, Amita, et al. “Safety, antitumor activity, and pharmacokineticsof dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial.” Cancer Chemotherapy and Pharmacology 89.1 (2022): 93-103.

8) Singh, Vanshikha, et al. “Dostarlimab as a miracle drug: rising hope against cancer treatment.” Biosensors 12.8 (2022): 617.

9) Costa, Bárbara, and Nuno Vale. “Dostarlimab: A Review.” Biomolecules 12.8 (2022): 1031.

10) Kristeleit, R. “Anti-tumour Activity and Updated Safety of the Poly (ADP- Ribose) Polymerase (PARP) Inhibitor Rucaparib as Monotherapy in Patients with Platinum-Sensitive, Relapsed, BRCA-Mutated, High-Grade Ovarian Cancer.” (2017).

11) Saha, Purabi, et al. “A Review of Immune Blockade Safety and Antitumor Activity of Dostarlimab Therapy in Endometrial Cancer.”International Journal for Research in Applied Sciences and Biotechnology 9.3 (2022): 201-209.

12) Kumar, Sujatha, et al. “Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models.” MAbs. Vol. 13. No. 1. Taylor & Francis, 2021.

13) Akodu, Busayo Odunayo, et al. “Dostarlimab: A Review of Its Pharmacology and Clinical Use in Management of Cancer.

14) Kasherman, L.; Ahrari, S.; Lheureux, S. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. FuturOncol. 2021, 17, 877–892.

15) , Abdullah, Israa M. Shamkh, and Amr Ahmed. “In Silico Inhibition of Three Cancer Inducing Receptors, IL-6, CTLA-4, and B7-2 by Dostarlimabmay explain the 100% Complete Recovery Rate in MMRd Locally Advanced Rectal Cancer seen in Pivotal ‘Immunoablative’Neoadjuvant Immunotherapy Clinical Trial. A Cancer Therapy Breakthrough.” (2022).

16) Fala, Loretta. “Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer.”

17) Syn, Nicholas L., et al. “De-novo and acquired resistance to immune checkpoint targeting.” The Lancet Oncology 18.12 (2017): e731-e741.

18) Markham, A. Dostarlimab: First Approval. Drugs 2021, 81, 1213–1219.

19) Kadam, Aishwarya V., et al. “Dostarlimab in the treatment of intermittent or primary advanced endometrial cancer.” Journal homepage: www. Ijrpr. Com ISSN 2582: 7421.

20) Lu, Sharon, et al. “An integrated analysis of dostarlimab immunogenicity.” The AAPS journal 23.5 (2021): 1-12.

21) Ul Hussain, Hassan, et al. “Dostarlimab: A breakthrough in the field of oncology.” Annals of Medicine and Surgery 80 (2022): 104046.

22) Neves da Silva, Helio V., et al. “Ocular adverse effects of therapeutic biologics.” Therapeutic Advances in Ophthalmology 14 (2022): 25158414211070878.

23) Petru, Edgar. “Endometrial cancer: news from ASCO.” Memo-Magazine of European Medical Oncology (2022): 1-3.

24) Mi, Mi, Chenyang Ye, and Ying Yuan. “Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer.” Signal Transduction and Targeted Therapy 7.1 (2022): 1-3.Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; LamendolaEssel, M.; El Dika, I.H.; Segal, N.; Shcherba, M.; Sugarman,

25) Cercek, A.; Lumish, M.; Sinopoli, J.; Weiss, J.; Shia, J.; Lamendola-Essel, M.; El Dika, I.H.; Segal, N.; Shcherba, M.; Sugarman,R.; et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N. Engl. J. Med. 2022, 386, 2363–2376.[CrossRef] [PubMed]

26) Germani, Marco Maria, et al. “The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients.” Cancer14.18 (2022): 4453.